|

Dato-DXd Clinical Trials

9 actively recruiting trials across 8 locations

No change since May 2026

Also known as: DS-1062, DS-1062a, Datopotamab Deruxtecan, Datopotamab deruxtecan (Dato-DXd, DS-1062a), IMP administration

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 3Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • AstraZeneca5
  • Daiichi Sankyo2
  • Memorial Sloan Kettering Cancer Center1
  • Gustave Roussy, Cancer Campus, Grand Paris1

Indications

Other1 trial

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
Phase 1/2

Daphne, Alabama1 trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Research Site

Phase 3

Fayetteville, Arkansas1 trial

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site

Phase 3

Little Rock, Arkansas1 trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Fullerton, California1 trial

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site

Phase 2/3

Irvine, California1 trial

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

City of Hope At Orange County Lennar Foundation Cancer Center

Phase 1

Santa Monica, California1 trial

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 2

Largo, Florida1 trial

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Research Site

Phase 3

Basking Ridge, New Jersey1 trial

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.